Virility Medical Files Patent Infringement Lawsuit Against Morari Medical

, /PRNewswire/ -- Virility Medical Ltd. ("Virility Medical"), a leading innovator in the sexual health industry, filed a patent infringement lawsuit on March 18, 2025, in the United States District Court for the District of Delaware against Morari, Inc. (d/b/a. Morari Medical).

The complaint asserts that Morari's MOR product infringes three United States patents owned by Virility Medical relating to Virility Medical's innovative and FDA cleared, in2 device (formerly known as vPatch, clearance number K223595). The complaint also seeks treble damages and a permanent injunction against the sale of the infringing MOR product.

Morari recently announced that it received clearance from the United States Food and Drug Administration ("FDA") to market the MOR product. As explained in the recently filed complaint, Morari's FDA submission asserted that the MOR product is "substantially equivalent" to Virility Medical's own FDA cleared product. Indeed, Morari's CEO, Jeff Bennett, has explained that Morari "leverage[ed]" Virility Medical's "existing research and technology" in order to "expedite [its] product's development and market entry."

The Virility Medical patents asserted in the complaint are U.S. Patent Nos. 10,773,072; 11,471,666; and 12,194,289. Virility Medical also owns additional patents and pending patent applications.

About Virility Medical

Virility Medical is a consumer healthcare company specializing in sexual health and dedicated to enhancing sexual wellbeing. Virility Medical's patented technology, which is marketed under the brand name in2, provides a drug-free treatment for premature ejaculation, one of the most common male sexual health concerns. The in2 device was subjected to clinical testing, resulting in marketing clearance from United States Food and Drug Administration, CE marking obtained for distribution in Europe under the MDR, and approval from the Israeli Ministry of Health.

SOURCE Virility Medical Ltd.